SAMSARA BIOCAPITAL, LLC

Registered adviser

CIK

1744967

Location

PALO ALTO, CA

Portfolio Value

Mid $1,217,460,852

Diversification

Moderately concentrated

Filing Date

Global Rank

#2,185 / 8,817 ▲ 48

Top Industry

Biotechnology 93.6%

Period ended 4 months ago

Filed Aug 14, 2026 · 2mo

26 quarters · since Mar 2020

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type

Registered adviser

Form ADV roster, Oct 1, 2026

Form ADV adviser

CRD 288114

Roster of Oct 1, 2026

Regulatory AUM

$2,170,095,404

Main clients

Pooled investment vehicles (100% of AUM)

Private funds

3 funds · Venture capital funds

Focus by fund count, roster of Oct 1, 2026

$2,319,440,625 gross assets

Private funds on Schedule D 7.B.(1)

As filed Mar 31, 2024; SEC's bulk Form ADV archive ends with 2024 filings.

$1,743,555,591 gross assets in 3 funds Venture capital funds $1,743,555,591 (3)

Form ADV history

Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.

Rosters	Regulatory AUM	Main clients
Apr 2026 to Oct 2026	$2,170,095,404	Pooled investment vehicles (100%)
Apr 2025 to Mar 2026	$1,859,634,308	Pooled investment vehicles (100%)
Apr 2024 to Mar 2025	$1,622,845,390	Pooled investment vehicles (100%)
May 2023 to Mar 2024	$1,365,987,964	Pooled investment vehicles (100%)
Apr 2023	$1,365,987,964	Pooled investment vehicles (100%)
May 2022 to Mar 2023	$1,144,019,216	Pooled investment vehicles (100%)

3 earlier changes not shown.

Portfolio style

Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.

Style

Concentrated

The top 10 positions are 90.5% of the book (60%+)

Turnover

Low turnover

13.5% over the last four quarters (under 30%)

Horizon

Horizon unknown

The value-weighted holding period is at least 11.5 quarters, but 2.9% of the book was already held when coverage starts

Closest benchmark: the Russell 2000 as of 2026-06-30, active share 99.6%; sector active share 90.9% against the combined 13F book's sector weights.

Over time 26 measured quarters

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

Portfolio Concentration

24 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026

Top Position

31.2%

−2.0 pts

Top 5

73.0%

−4.1 pts

Top 10

90.5%

−2.1 pts

HHI

1,534

Moderately concentrated−166

Portfolio Trend

26 quarters · across all stocks

Sector Breakdown

As of Jun 30, 2026

Sector	% Portfolio	Value	Positions
Healthcare	100.0%	$1,217,460,852	24

Last Quarter's Activity

Export CSV

Jun 30, 2026 vs Mar 31, 2026

Added To

Positions the filer increased

2 positions

Ticker	Company	Δ Shares	Shares	Value
RANI	Rani Therapeutics Holdings, Inc.	+1,869,159	10,369,159	$7,880,560
IVA	Inventiva S.A.	+1,120,000	6,314,805	$23,869,962
No positions match the current search.

Trimmed

Positions the filer reduced

5 positions

Ticker	Company	Δ Shares	Shares	Value
XFOR	X4 Pharmaceuticals, Inc	−436,979	1,395,587	$6,517,391
UPB	Upstream Bio, Inc.	−382,330	353,717	$2,447,721
JBIO	Jade Biosciences, Inc.	−232,561	736,237	$16,359,186
KLRS	Kalaris Therapeutics, Inc.	−66,906	12,881,175	$52,426,382
ABVX	Abivax S.A.	−1,486	55,095	$7,341,959
No positions match the current search.

New Positions

Positions the filer opened this quarter

4 positions

Ticker	Company	Shares	Value
ALMR	Alamar Biosciences, Inc.	2,480,310	$67,191,597
PBLS	Parabilis Medicines, Inc.	556,044	$15,218,924
ARTV	Artiva Biotherapeutics, Inc.	954,861	$9,262,151
ELOX	Eloxx Pharmaceuticals, Inc.	400,000	$5,552,000
No positions match the current search.

Sold Out

Positions the filer fully exited

2 positions

Ticker	Company	Shares	Value
PVLA	Palvella Therapeutics, Inc.	38,432	$4,790,548
—		60,873	$0
No positions match the current search.

Portfolio Positions

Compact Export CSV View 13F filing

24 tracked positions · $1,217,460,852 total · filing declares 24 positions · $1,217,462,122 · as of Jun 30, 2026

All sectors Healthcare

Ticker	Company	Type	Shares	Δ Shares	Value (USD)	% Δ Value	Held (qtrs)	Est. cost/share	% of Portfolio
SRRK	Scholar Rock Holding Corp Healthcare	Held	6,897,652	0	$379,370,860	+11.9%	18	$14.61	31.16%
ALMS	Alumis Inc. Healthcare	Held	6,345,219	0	$178,554,462	+27.7%	8	$10.75	14.67%
MLYS	Mineralys Therapeutics, Inc. Healthcare	Held	5,871,018	0	$158,400,065	−0.4%	14	$16.38	13.01%
SEPN	Septerna, Inc. Healthcare	Held	3,149,128	0	$105,464,296	+39.4%	7	$22.17	8.66%
ALMR	Alamar Biosciences, Inc. Healthcare	NEW	2,480,310	NEW	$67,191,597	NEW	1	$22.63	5.52%
NGNE	Neurogene Inc. Healthcare	Held	1,717,127	0	$54,003,644	+56.0%	11	unpriced	4.44%
KLRS	Kalaris Therapeutics, Inc. Healthcare	Reduced	12,881,175	-66,906	$52,426,382	−29.8%	6	unpriced	4.31%
SGP	SpyGlass Pharma, Inc. Healthcare	Held	2,109,953	0	$46,967,553	−14.1%	2	$26.90	3.86%
STRO	Sutro Biopharma, Inc. Healthcare	Held	1,062,872	0	$35,287,350	+33.3%	26+	before history	2.90%
IVA	Inventiva S.A. Healthcare	Added	6,314,805	+1,120,000	$23,869,962	−17.2%	3	$4.67	1.96%
JBIO	Jade Biosciences, Inc. Healthcare	Reduced	736,237	-232,561	$16,359,186	+20.2%	5	unpriced	1.34%
PBLS	Parabilis Medicines, Inc. Healthcare	NEW	556,044	NEW	$15,218,924	NEW	1	unpriced	1.25%
VTVT	vTv Therapeutics Inc. Healthcare	Held	298,496	0	$11,238,374	−5.1%	19	$19.35	0.92%
AQST	Aquestive Therapeutics, Inc. Healthcare	Held	2,500,000	0	$10,400,000	+0.2%	4	$4.32	0.85%
NKTX	Nkarta, Inc. Healthcare	Held	3,507,666	0	$9,926,694	+34.1%	24	$21.30	0.82%
ARTV	Artiva Biotherapeutics, Inc. Healthcare	NEW	954,861	NEW	$9,262,151	NEW	1	$9.11	0.76%
RANI	Rani Therapeutics Holdings, Inc. Healthcare	Added	10,369,159	+1,869,159	$7,880,560	+26.1%	3	$1.40	0.65%
AGMB	AgomAb Therapeutics NV Healthcare	Held	600,000	0	$7,788,000	+23.7%	2	$14.16	0.64%
ABVX	Abivax S.A. Healthcare	Reduced	55,095	-1,486	$7,341,959	+16.5%	4	$61.30	0.60%
XFOR	X4 Pharmaceuticals, Inc Healthcare	Reduced	1,395,587	-436,979	$6,517,391	−13.9%	3	$3.63	0.54%
ELOX	Eloxx Pharmaceuticals, Inc. Healthcare	NEW	400,000	NEW	$5,552,000	NEW	1	unpriced	0.46%
CHRS	Coherus Oncology, Inc. Healthcare	Held	3,428,571	0	$4,799,999	−17.2%	2	$1.78	0.39%
UPB	Upstream Bio, Inc. Healthcare	Reduced	353,717	-382,330	$2,447,721	−63.1%	7	$22.33	0.20%
GOSS	Gossamer Bio, Inc. Healthcare	Held	7,222,559	0	$1,191,722	−49.8%	12	$1.41	0.10%

Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.